Cardiol Therapeutics Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Cardiol Therapeutics Inc. now
Current reporting with the operating signal separated from the noise.
Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
Investors are testing whether Cardiol Therapeutics Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Cardiol Therapeutics Inc.: Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
The story matters when it changes Cardiol Therapeutics Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Cardiol Therapeutics Inc. (CRDL) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Investors are testing whether Cardiol Therapeutics Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest CRDL filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Cardiol Therapeutics Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →